A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

246

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: Sonrotoclax
DRUG: Dexamethasone
DRUG: Carfilzomib
DRUG: Daratumumab
DRUG: Pomalidomide

Sponsor

BeOne Medicines